Document is current

Article History

Accepted: 22 February 2023

First Online: 14 April 2023

Compliance with Ethical Standards

:

: None of the authors has any interest to report directly related to this manuscript.Outside the scope of this manuscript:<b>Silvia Stacchiotti</b> reports honoraria from Aadi, Boehringer, Glaxo Smith Kline, Pharmamar, Gentili; participation on a Data Safety Monitoring Board or Advisory Board for Astex Pharmaceuticals, Bayer, Bavarian Nordic, Boehringer, Daiichi Sankyo, Glaxo Smith Kline, Ikena, Maxivax, Novartis, PharmaMar, Rain Therapeutic, Servier, SpringWorks; support for attending meetings and/or travel Pharmamar; unpaid leadership in Member of the Scientific Advisory Board of the Chordoma Foundation, Member of the Scientific Advisory Board of the Desmoid Foundation, Member of the Scientific Advisory Board of the Epithelioid Hemangioendothelioma Group, Member of the Scientific Advisory Board of the Leiomyosarcoma Foundation.<b>William Tap</b> reports personal fees from Eli Lilly, personal fees from EMD Serono, personal fees from Mundipharma, personal fees from C4 Therapeutics, personal fees from Daiichi Sankyo, personal fees from Deciphera, personal fees from Adcendo, personal fees from Ayala Pharmaceuticals, personal fees from Kowa, personal fees from Servier, personal fees from Bayer Pharmaceuticals, personal fees from Epizyme, personal fees from Cogent, personal fees from Medpacto, personal fees from Foghorn Therapeutics, personal fees from Amgen, personal fees from AmMax Bio, personal fees from Boehringer Ingelheim, personal fees from BioAtla, personal fees from Inhibrx, outside the submitted work; In addition, Dr. Tap has a patent Companion Diagnostic for CDK4 inhibitors—14/854,329 pending to MSKCC/SKI, and a patent Enigma and CDH18 as companion Diagnostics for CDK4 inhibition—SKI2016-021–03 pending to MSKCC/SKI and Scientific Advisory Board—Certis Oncology Solutions, Stock OwnershipÜo-Founder—Atropos Therapeutics, Stock Ownership-Scientific Advisory Board Innova Therapeutics.<b>Hugh Leonard:</b> No conflict of interest to declare.<b>Nadia Zaffaroni:</b> Research funding to my institution for studies in which I am involved: Ikena.<b>Giacomo G Baldi</b> reports consulting fees from Eli Lilly, Pharmamar, AboutEvents, Boehringer Ingelheim; honoraria from Pharmamar, Eli Lilly, Glaxo Smith Kline, Merck Sharp & Dome, Eisai; support for attending meetings and/or travels from Novartis, Pharmamar, Eli Lilly; participation on advisory board from Pharmamar, Eli Lilly, Glaxo Smith Kline, Merck Sharp & Dome, Eisai, Boehringer Ingelheim, outside the submitted work.

: All reported studies/experiments with human or animal subjects performed by the authors have been previously published and complied with all applicable ethical standards (including the Helsinki declaration and its amendments, institutional/national research committee standards, and international/national/institutional guidelines).